Auckland Bioengineering Institute


Zoar Engelman

engelman-zoar

Alumnus profile

Zoar Engelman received a Bachelor of Science and Master of Science in Biomedical Engineering from the University of Utah in 2003 and 2005, respectively. His Master's thesis dealt with the ventricular repolarisation in an acute model of pharmacologically induced long QT syndrome.

Zoar began studying for his doctorate in Bioengineering at the Auckland Bioengineering Institute in 2006 at which time he became a member of the Cardiac Electrophysiology research group led by Professor Bruce Smaill.

Zoar's doctoral research focused on characterising how tissue remodelling is associated with structural heart disease and myocardial infarction affects cardiac tissue electrophysiology. Zoar used a combination of mathematical modelling, 3D intramural recordings in the infarct boarder zone, noncontact mapping of the LV endocardium, ultrasound, MRI, diffusion tensor MRI, and 3D registered histology. He sought to explain the role that structural anisotropy plays as an arrhythmic substrate.

On completing his doctorate in 2011, Zoar spent a brief period with the US company Coridea as a Senior Biomedical Systems Engineer, then moved to medical device company Cibiem Inc, where he is now Research Director.

Coridea is an idea generator, technology incubator and consulting firm focused on the cardio-renal and cardio-pulmonary fields. The venture was founded in 1998 by cardiologist Dr Howard Levin and Mark Gelfand, a biomedical engineer, who met at Johns Hopkins University in the late 1980s. Cibiem is one of four venture funded startup companies launched by Coridea.

Zoar develops and validates novel therapies for the treatment of hypertension and heart failure. He manages systems for use in clinical and experimental studies, oversee these studies, and use the results to drive future studies.

Zoar's long term professional goal is to use his integrated knowledge of engineering and physiology together with his passion for medical science to identify and develop new technologies that improve patient care.